Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
d. Any other systemic anti-cancer therapy
e. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
b. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
c. Nivolumab monotherapy
d. Nivolumab and Ipilimumab
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:
a. Oesophageal cancer (any type or stage)
b. Oesophageal adenocarcinoma (any stage)
c. Oesophageal squamous cell carcinoma (any stage)
d. Gastric cancer (any type or stage)
e. Cancer of the gastro-oesophageal junction (any stage)
